- Home
- JBLU vs ATAI Comparison
JBLU vs ATAI Comparison
Compare JBLU & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBLU | ATAI |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2002 | 2025 |
Fundamental Metrics
Financial Performance| Metric | JBLU | ATAI |
|---|---|---|
| Price | $5.25 | $4.61 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.91 | ★ $15.88 |
| AVG Volume (30 Days) | ★ 26.9M | 6.3M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,062,000,000.00 | $4,089,000.00 |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $3.86 | $1.29 |
| 52 Week High | $6.46 | $6.73 |
Technical Indicators
Market Signals| Indicator | JBLU | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 62.74 |
| Support Level | $4.74 | $3.41 |
| Resistance Level | $5.66 | $4.68 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 49.03 | 51.93 |
Price Performance
Historical ComparisonAbout JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.